Development of 2,2-dimethylchromanol cysteinyl LT1 receptor antagonists

  • Bioorg Med Chem Lett. 1998 Dec 15;8(24):3577-82. doi: 10.1016/s0960-894x(98)00654-4.
R J Chambers  1 ,  G W Antognoli ,  J B Cheng ,  A V Kuperman ,  T C Liston ,  A Marfat ,  B S Owens ,  J S Pillar ,  J T Shirley ,  J W Watson
Affiliations
  • 1. Central Research Division, Pfizer Inc., Groton, CT 06340, USA.
PMID: 9934474 DOI: 10.1016/s0960-894x(98)00654-4
Abstract

A new series of cysLT1 receptor antagonists represented by CP-288,886 (7) and CP-265,298 (8) were developed which are equipotent to clinical cysLT1 receptor antagonists Zafirlukast (1) and Pranlukast (2).

Products